Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Regenerated chimeric RNAs as biomarkers enriched in human prostate cancer

A technology for prostate cancer and cancer, applied in the fields of cell biology, pharmacology, and molecular biology, can solve the problem of increasing chimeric RNA without research

Inactive Publication Date: 2016-06-08
BAYLOR COLLEGE OF MEDICINE
View PDF96 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This result raises the possibility that chimeric RNAs in cancer have not been studied and are generally unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Regenerated chimeric RNAs as biomarkers enriched in human prostate cancer
  • Regenerated chimeric RNAs as biomarkers enriched in human prostate cancer
  • Regenerated chimeric RNAs as biomarkers enriched in human prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0168] Identification of novel regenerative chimeric RNAs in prostate cancer

[0169] To identify chimeric RNAs expressed in prostate cancer, the inventors sequenced the transcriptomes of 20 cancer samples and 10 matched benign samples from prostate cancer patients. This patient did not undergo prostatectomy prior to radical prostatectomy. A Genome Sequencer (Illumina) was used for sequencing of these samples to generate output sequence pairs of 36 nucleotide reads. A total of 30 lanes of a genome sequencer (Illumina) were used to generate ~1.3 billion raw sequence reads. Using stringent filters (see Example 9), the inventors obtained nearly 5 million reads that could be uniquely mapped to the human genome and met our additional bioinformatics criteria.

[0170] A strategy for identifying chimeric RNAs is to search for pairs of chimeric reads by each read mapping to a distinct gene in the genome or transcriptome ( figure 1 ). To minimize false positives, the inventors requ...

example 2

[0188] Regeneration of chimeric RNA in cancer vs benign matched samples

[0189] To evaluate its differential expression in cancer vs benign matched samples, the inventors mapped the number of chimeric and splice reads supported by each chimeric RNA and its regeneration rate for each patient. Such as image 3 As shown, most of the chimeric RNAs validated appeared to be highly reproducible in cancer samples, although most of them were also benign matched tissues from radical prostatectomy (however less frequent). This included TMPRSS2-ERG as a control, which is a known cancer specific drug (9). The presence of chimeric RNA in matched benign samples may represent a "field effect" of histologically normal epithelium with multiple premalignant lesions preceding histological changes (17). Additionally, small cancer lesions may be present in some matched benign samples, since the tissue was not histologically evaluated throughout the tissue used for RNA extraction. Nonetheless, s...

example 3

[0196] Expression of Chimeric RNA in Prostate Cancer Cell Lines

[0197] Because the identified chimeric RNAs are easily regenerated in human prostate cancer samples, the inventors believe that these chimeric RNAs can also be present in the established prostate cell lines in some embodiments. Therefore, the inventors tested the expression of these chimeric RNAs in prostate-derived cancer cell lines, including androgen receptor-negative cell lines (PC3 and DU145) and androgen-sensitive cell lines (LNCaP, VCAP, and LAPC4) , and immortalized prostate epithelial cells (PNTla) for comparison with non-cancerous primary human prostate epithelial cells (PREC). RT-PCR results showed that most of the chimeric RNAs among the 32 chimeras in the cancer cell lines (Table 4) showed different expression profiles. However, nine chimeric RNAs were significantly absent in non-cancer PrEC (Table 4 and Figure 4 B). These RNAs included TMEM79-SMG5, the same chimera detected by RT-PCR in cancer ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention includes embodiments using chimeric RNAs associated with cancer. In certain embodiments, the presence of cancer or an increased risk of cancer is determined based on the identification of one or more specific chimeric RNAs. In particular aspects, one or more chimeric RNAs are used in the diagnosis of prostate cancer. In certain aspects, the chimeric RNA is TMEM79-SMG5 RNA.

Description

[0001] This application claims priority to US Provisional Patent Application No. 61 / 480,005, filed April 28, 2011, which is hereby incorporated by reference in its entirety. [0002] This application was made with government support under US Department of Defense Idea Development Award PC093918 awarded by the US Department of Defense. The Government therefore has certain rights in this invention. technical field [0003] The present invention relates at least to the fields of molecular biology, cell biology and pharmacology (including the field of cancer medicine). In a particular aspect, the invention relates to cancer diagnosis. Background technique [0004] Chimeric RNAs unrelated to chromosomal rearrangements are primarily generated by two mechanisms of transcription induction (1,2). The first mechanism is "read-through / splice". Here the chimeric RNA starts at the upstream gene and ends at the end of the adjacent downstream gene, with the segment in between removed by...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07H21/02C12Q1/68
CPCC12Q1/6886C12Q2600/156C12Q2600/158
Inventor 严来兴卡尔帕娜·康南
Owner BAYLOR COLLEGE OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com